Abstract
<b>Abstract ID 26122</b> <b>Poster Board 264</b> <b>Objectives:</b> Kratom (Mitragynine speciosa), a natural product from southeast Asia, has become a popular self-treatment trend for pain and opioid use disorder (OUD) and users claim great success. Considering the current opioid epidemic, kratom is being studied as a potential OUD pharmacotherapy. Given that respiratory depression is a major cause of mortality due to opioid overdose, a great need exists to determine kratom-related respiratory effects alone and in the presence of opioids. For the current study we examined the effects of mitragynine, the most abundant alkaloid in kratom, in a rat model of intravenous (i.v.) administered morphine-induced respiratory depression. <b>Methods:</b> Adult male and female Sprague Dawley rats arrived pre-implanted with a jugular catheter. Experiments were conducted using a within-subjects experimental design over 8 weeks and each session lasted 3 hours. During a 3-hour session, respiratory parameters including respiratory frequency, tidal volume, and minute ventilation were measured using whole body plesmography in freely moving animals. A 3-hour session was comprised of a 1-hour acclimation, followed by a 20-minute baseline. The first i.v. infusion was delivered at the end of the baseline and the second i.v. infusion was delivered 5 minutes later. After the second infusion the above-mentioned respiratory parameters were continuously monitored for 110 minutes. A 7-day drug washout period between sessions was utilized, and session were counterbalanced with no more than 2 animals of the same sex receiving the same condition on the same day. In all experiments a solution consisting of 0.9% saline, tween, polyethylene, and propylene glycol served as vehicle for mitragynine, morphine was dissolved in 0.9% saline. <b>Results:</b> Saline + vehicle had no effect on the respiratory parameters measured. Morphine (32 mg/kg, i.v.) followed by vehicle injection produced robust respiratory depression as indicated by decreased frequency, tidal volume, and minute ventilation for the duration of the study. Mitragynine (10 mg/kg, i.v.) followed by vehicle injection significantly increased respiratory frequency and minute ventilation but did not alter tidal volume. When morphine (32 mg/kg, i.v.) was delivered before mitragynine (10 mg/kg, i.v.) no significant differences were observed in respiratory frequency, tidal volume, or minute ventilation compared to the morphine + vehicle administration results. However, when mitragynine (10 mg/kg, i.v.) was delivered first, 5 minutes prior to morphine (32 mg/kg, i.v.) mitragynine prevented opioid induced respiratory depression, as indicated by decreased frequency, tidal volume, and minute ventilation. <b>Conclusions:</b> Intravenously administered morphine produced robust respiratory depression symptoms, whereas at the dose studied here, mitragynine did not. When given after morphine, mitragynine failed to alter morphine-induced respiratory depression symptoms. However, when given before morphine, mitragynine prevented morphine-induced respiratory depression. These findings have important implications in opioid use disorder and opioid overdose medication development. Supported by National Institute on Drug Abuse grants DA25267 and DA048353.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have